NCT03944707 - Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions

Asthma

Interventions

DRUG

LOU064 100 mg

LOU064 100 mg once daily orally administered as two 50 mg capsules

DRUG

Placebo

Placebo once daily administered orally as capsules

Trial Locations (19)

10787

Novartis Investigative Site, Berlin

12159

Novartis Investigative Site, Berlin

20354

Novartis Investigative Site, Hamburg

27607

Novartis Investigative Site, Raleigh

30033

Novartis Investigative Site, Krakow

30173

Novartis Investigative Site, Hanover

60596

Novartis Investigative Site, Frankfurt

63141

Novartis Investigative Site, St Louis

80230

Novartis Investigative Site, Denver

196143

Novartis Investigative Site, Saint Petersburg

432063

Novartis Investigative Site, Ulyanovsk

02747

Novartis Investigative Site, North Dartmouth

C1056ABJ

Novartis Investigative Site, CABA

C1425BEN

Novartis Investigative Site, CABA

S2000DBS

Novartis Investigative Site, Rosario

S2000JKR

Novartis Investigative Site, Rosario

15-430

Novartis Investigative Site, Biaystok

86-300

Novartis Investigative Site, Grudziądz

60 823

Novartis Investigative Site, Poznan